These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36045377)

  • 1. Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.
    Enzing JJ; Knies S; Engel J; IJzerman MJ; Sander B; Vreman R; Boer B; Brouwer WBF
    Cost Eff Resour Alloc; 2022 Aug; 20(1):46. PubMed ID: 36045377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
    Goldhaber-Fiebert JD; Cipriano LE
    Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers.
    Enzing JJ; Himmler S; Knies S; Brouwer WBF
    Value Health; 2022 Feb; 25(2):222-229. PubMed ID: 35094795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
    Blonda A; Barcina Lacosta T; Toumi M; Simoens S
    Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
    [No Abstract]   [Full Text] [Related]  

  • 7. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
    Huang C; Ung COL; Wushouer H; Bai L; Huang T; Li X; Guan X; Shi L
    Health Res Policy Syst; 2022 Jan; 20(1):3. PubMed ID: 34980159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
    Rand LZ; Kesselheim AS
    J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual health services.
    Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
    GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health technology assessment of biosimilars worldwide: a scoping review.
    Ascef BO; Lopes ACF; de Soárez PC
    Health Res Policy Syst; 2020 Aug; 18(1):95. PubMed ID: 32843051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capacity Building for Health Technology Assessment in Jordan: Institutionalization and Its Use in Pricing and Reimbursement Decisions.
    Almomani E; Hammad EA; AlQutob R; Hammour KA; Al-Sharu E; Abu-Shaer M; Alabbadi I; Kaló Z
    Value Health Reg Issues; 2022 Nov; 32():47-53. PubMed ID: 36075139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses.
    Mirzayeh Fashami F; Tarride JE; Sadeghirad B; Hariri K; Peyrovinasab A; Levine M
    Pharmacoecon Open; 2024 Nov; 8(6):823-836. PubMed ID: 39103675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.